246 related articles for article (PubMed ID: 28263920)
1. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach.
Mau LW; Preussler JM; Burns LJ; Leppke S; Majhail NS; Meyer CL; Mupfudze T; Saber W; Steinert P; Vanness DJ
Pharmacoeconomics; 2020 May; 38(5):515-526. PubMed ID: 32128725
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.
Stein EM; Bonifacio G; Latremouille-Viau D; Guerin A; Shi S; Gagnon-Sanschagrin P; Briggs O; Joseph GJ
J Med Econ; 2018 Jun; 21(6):556-563. PubMed ID: 29304724
[TBL] [Abstract][Full Text] [Related]
4. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
5. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
Hagiwara M; Sharma A; Chung KC; Delea TE
J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
[TBL] [Abstract][Full Text] [Related]
6. Trends in Allogeneic Hematopoietic Cell Transplantation Utilization and Estimated Unmet Need Among Medicare Beneficiaries with Acute Myelogenous Leukemia.
Mau LW; Preussler JM; Meyer CL; Senneka MK; Wallerstedt S; Steinert P; Khera N; Saber W
Transplant Cell Ther; 2022 Dec; 28(12):852-858. PubMed ID: 36170959
[TBL] [Abstract][Full Text] [Related]
7. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
[TBL] [Abstract][Full Text] [Related]
9. Administrative Claims Data for Economic Analyses in Hematopoietic Cell Transplantation: Challenges and Opportunities.
Preussler JM; Mau LW; Majhail NS; Meyer CL; Denzen EM; Edsall KC; Farnia SH; Silver A; Saber W; Burns LJ; Vanness DJ
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1738-1746. PubMed ID: 27184624
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.
Arnold SD; Brazauskas R; He N; Li Y; Hall M; Atsuta Y; Dalal J; Hahn T; Khera N; Bonfim C; Hashmi S; Parsons S; Wood WA; Steinberg A; Freytes CO; Dandoy CE; Marks DI; Lazarus HM; Abdel-Azim H; Bitan M; Diaz MA; Olsson RF; Gergis U; Seber A; Wirk B; LeMaistre CF; Ustun C; Duncan C; Rizzieri D; Szwajcer D; Fagioli F; Frangoul H; Knight JM; Kamble RT; Mehta P; Schears R; Satwani P; Pulsipher MA; Aplenc R; Saber W
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1747-1756. PubMed ID: 32464284
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota V
Leuk Res; 2018 Aug; 71():27-33. PubMed ID: 29944984
[TBL] [Abstract][Full Text] [Related]
13. Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium.
Van de Velde AL; Beutels P; Smits EL; Van Tendeloo VF; Nijs G; Anguille S; Verlinden A; Gadisseur AP; Schroyens WA; Dom S; Cornille I; Goossens H; Berneman ZN
Leuk Res; 2016 Jul; 46():26-9. PubMed ID: 27111858
[TBL] [Abstract][Full Text] [Related]
14. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands.
Leunis A; Blommestein HM; Huijgens PC; Blijlevens NM; Jongen-Lavrencic M; Uyl-de Groot CA
Leuk Res; 2013 Mar; 37(3):245-50. PubMed ID: 23069745
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan.
Huang HH; Chen CM; Wang CY; Hsu WW; Chen HM; Ko BS; Hsiao FY
PLoS One; 2022; 17(1):e0261871. PubMed ID: 35061709
[TBL] [Abstract][Full Text] [Related]
16. Healthcare expenses for treatment of acute myeloid leukemia.
Bewersdorf JP; Shallis RM; Wang R; Huntington SF; Perreault S; Ma X; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):641-650. PubMed ID: 31159602
[No Abstract] [Full Text] [Related]
17. Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia.
Chen GL; Liu H; Zhang Y; Thomas J; Ross M; Wang ES; Block AW; Sait S; Deeb G; Wallace P; Wetzler M; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1369-74. PubMed ID: 24867777
[TBL] [Abstract][Full Text] [Related]
18. Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.
Vaughn JE; Othus M; Powell MA; Gardner KM; Rizzuto DL; Hendrie PC; Becker PS; Pottinger PS; Estey EH; Walter RB
JAMA Oncol; 2015 Nov; 1(8):1120-7. PubMed ID: 26355382
[TBL] [Abstract][Full Text] [Related]
19. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
[TBL] [Abstract][Full Text] [Related]
20. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
Brunner AM; Huggar D; Copher R; Zhou ZY; Zichlin ML; Anderson A; Downes N; McBride A
Leuk Res; 2023 Sep; 132():107353. PubMed ID: 37562330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
